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Complementary DNA clones corresponding to human brain nitric oxide (NO) synthase have been isolated. The deduced amino acid sequence 
revealed an overall identity with rat brain NO synthase of about 93% and contained all suggested consensus sites for binding of the co-factors. 
The cDNA transfected COS-1 cells showed significant NO synthase activity with the typical co-factor requirements. Unexpectedly, messenger RNA 
levels of this isoform of NO synthase was more abundant in human skeletal muscle than human brain. Moreover, we detected high NO synthase 
activity and the expressed protein in human skeletal muscle by Western blot analysis, indicating a possible novel function of NO in skeletal muscle. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Nitric oxide (NO) is a ubiquitous paracrine substance 
and can also act as an intracellular second messenger in 
various cells and tissues [l-3]. In brain and neuronal 
cells, NO is synthesized from L-arginine by NO synthase 
(EC 1.14.23) in a Ca2+/calmodulin (CaM)-dependent 
manner [4--61. NO mediates the stimulatory actions of 
neurotransmitters on the intracellular concentration of 
cyclic GMP [3]. NO has also been shown to be involved 
in long-term depression and long-term potentiation, 
suggesting the possibility of playing a vital role in mem- 
ory and learning [7-l 13. 
Recently, Bredt et al. have cloned a cDNA for rat 
brain NO synthase and showed a close homology with 
cytochrome P-450 reductase [12]. We report here the 
isolation, functional expression of human brain NO 
synthase cDNA, and evidence that NO synthase is 
highly expressed in human skeletal muscle. 
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2.1. Screening of the human cerebellum cDNA library 
Using published 32-mer oligonucleotide sequences of rat brain NO 
synthase [12], we performed polymerase chain reaction (PCR) on 
first-strand rat cerebellum cDNA and produced a 599-bp fragment. 
This fragment was subcloned into pBluescript SK(-) (Stratagene, La 
Jolla, CA) and sequenced. A human cerebellum cDNA library in 
igtl 1 (Clontech, Palo Alto, CA) was screened using the “P-labeled 
fragment as a probe. The nylon filters (Hybond-N, Amersham, Ar- 
lington Hights, IL) were hybridized at 42°C for 24 h in 50 mM 
Tris-HCl, pH 7.5,l M NaCl, 10 x Denhardt’s olution, 1% SDS, 10% 
dextran sulfate, 100 &ml denatured salmon sperm DNA and the 
“P-labeled probe, and washed at 42’C with 6 x SSC containing 1% 
SDS. Blots were exposed overnight to Kodak XAR film at - 80°C. 
Positive clones were purified, and the inserts were subcloned into the 
EcoRI site of plluescript. Restriction fragments were subcloned into 
pBluescript and sequenced by the dideoxy chain termination method 
using Sequenase (United States Biochemicals, Cleveland, OH). 
2.2. Expression in mammalian cells 
The cDNAs of #5 and #18 clones were ligated at the unique BfrI 
site (position 1,394) to make a cDNA that contains the full open 
reading frame for NO synthase. The insert was subcloned into the 
expression vectors, pcDL-SRa (Y. Takebe, National Institute of 
Health, Tokyo, Japan, [13]) and pcDNA I (Invitrogen, San Diego, 
CA). About 50% confluent COS-1 cells in 60-mm dishes were trans- 
fected with the complex of 3 ,ug DNA and 30 pg Lipofectin (Gibco- 
BRL, Gaithersburg, MD) in 2.5 ml of Opti-MEM (Gibco-BRL), and 
incubated for 5 h at 37°C in a CO* incubator. The medium was 
replaced with DMEM containing 10% serum and the cells were incu- 
bated for another 2 days. The cells were suspended in 0.1 ml of 50 mM 
HEPES (pH 7.4) 0.1 mM EDTA, 100 PM PMSF, 1 PM pepstatin, 
1 PM leupeptin, 0.3 PM aprotinin, and freeze-thawed 3 times using 
liquid nitrogen. NO synthase activity in the homogenate was measured 
as described below. 
2.3. Northern blot analysis 
The Human multi-tissue Northern blot filter (Clontech) was hybrid- 
ized at 42°C for 24 h in 50% formamide, 5 x SSPE, 10 x Denhardt’s 
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solution, 2% SDS. 100 &ml salmon sperm DNA and the “P-labeled 
probe, and washed at 50°C for 1 h with 0.1 x SSC containing 0.1% 
SDS. Blots were exposed to Kodak XAR film at - 80°C for 4 days. 
2.4. Assay of NO synthase 
Human skeletal muscle tissue (45-year-old male, International Insti- 
tute for the Advancement of Medicine, Exton, PA) was homogenized 
in 5 ~01s. of buffer (50 mM Tris-HCl, pH 7.5 containing 1 mM EDTA, 
5 mM 2-mercaptoethanol, 10 ,&ml pepstatin, 10 ,&ml aprotinin, 10 
&ml leupeptin and 100 &ml PMSF), and centrifuged at 105 000 x g
for 60 min. The pellet was washed twice with the equal volume of the 
buffer containing 1 M KCI. The KCI-washed pellet was resuspended 
in the buffer (without KCI). NO synthase activity was measured by 
the conversion of [ZH]arginine to [‘Hlcitrulline as described [6,14]. 
Samples (50~1) were incubated in 50 mM HEPES, pH 7.4 with 10,~M 
L-[2,3,4,5-‘Hlarginine (9.8 GBq/mmol), 1 mM NADPH, 100 PM 
CaCIZ, 30 nM CaM, 3 PM BH,, 1 PM FAD and I ,uM FMN in a final 
volume of 100 ~1. The reaction was carried out for 10 min at 37°C and 
terminated by adding 0.5 ml of 20 mM HEPES, pH 5.5, containing 
2 mM EDTA and 2 mM EGTA. The incubates were applied to 1 ml 
columns of Dowex AG50WX-8 (Na’form) and eluted three times with 
0.5 ml of the above buffer. All the liquid was pooled and radioactivity 
was determined by liquid scintillation counting. Protein was measured 
using the Bradford reagent [ 151 with bovine serum albumin as a stand- 
ard. 
2.5. Western blot analysis 
The fractions (50 fig protein) were separated on 8% SDS-poly- 
acrylamide gels and the proteins were blotted onto nitrocellulose mem- 
brane. The membrane was blocked with 6% non-fat dried milk, and 
subsequently incubated with the polyclonal antibody against rat brain 
NO synthase (6781-8) [16], or the monoclonal antibody against bovme 
aortic endothelial NO synthase (H32) [17]. The specific proteins were 
detected by enhanced chemiluminescence (ECL, Amersham). 
3. RESULTS 
A human cerebellum ilgtll cDNA library was 
screened with the PCR fragment of rat brain NO syn- 
thase at low stringency. After repeated cloning, one 
positive clone (#l 920), which showed a highly homolo- 
gous deduced amino acid sequence with rat brain NO 
synthase [12], was isolated. Since the clone had only a 
partial coding region, the same library was re-screened 
using the BarnHI fragments from both ends of the 
cDNA (400 bp and 300 bp) as probes, and #5 and #18 
clones were isolated and sequenced. Based on the con- 
sensus sequence for the translational start site [18], the 
ATG at position 430 defines the beginning of an open 
reading frame. The open reading frame from position 
430 to position 4,728 encodes for 1,433 amino acids 
(Fig. 1). The calculated molecular weight of the protein 
was 16,1037 Da, which is consistent with that deter- 
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Fig. 1. Alignment of deduced ammo acid sequences of NO synthases from human brain (upper sequence) and rat brain (lower sequence). Regions 
of identity are indicated by bars, and that of similarity are indicated by double dots or a single dot, according to the evolutionary distance between 
the amino acids [30]. Consensus sequences of co-factor bindmg regions for CaM, FMN, FAD pyrophosphate (FAD-PPi), FAD lsoalloxazme 
(FAD-ISO), NADPH ribose (NADPH-rib), NADPH adenine (NADPH-Ade) are boxed. The nucleotide sequence has been submltted to the 
GenBanWEMBL Data Bank with accession number LO2881 
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Fig. 2. Transient expression of cDNAs of NO synthase in COS-1 cells. (A) COS-1 cells were transfected with the indicated plasmids, and NO 
synthase activity in the homogenate was assayed as described in Materials and Methods. (B) COS-1 cells were transfected with sense NO synthase 
cDNA/pcDNA I, and NO synthase activity in the homogenate with various conditions as indicated was measured. Results are the means of duplicate 
determinations. 
mined by Western blot analysis using anti-brain NO 
synthase [19]. Comparison of the deduced amino acid 
sequence of human brain NO synthase to that of rat 
brain enzyme revealed a high homology (93%), al- 
though the human enzyme was 4 amino acids longer 
than the rat enzyme (Fig. 1). The human NO synthase 
also contained all the suggested consensus binding sites 
for CaM, FAD, FMN and NADPH, and the sequences 
of these sites were identical with that of rat enzyme. 
We subcloned the cDNA with full coding sequence 
into the EcoRI site of the pcDL-SRa expression vector 
[13] and the pcDNA I expression vector (human cy- 
tomegalovirus enhancer/promoter). Two days after 
transfection, the COS-1 cell homogenate was assayed 
for NO synthase activity using the conversion of L- 
arginine to L-citrulline (Fig. 2). Only the cells trans- 
Fig. 3. Northern blot analysis of human NO synthase type I mRNA. 
Poly(A)’ RNAs (2pg) from heart, brain, placenta, lung, liver, skeletal 
muscle, kidney, and pancreas from human were hybridized with the 
32P-lab&d cDNA as described in Materials and Methods. RNA lad- 
der (Gibco-BRL) was used as a size standard. Sk. Muscle, skeletal 
muscle. 
4.4 
2.4 
. 
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fected with sense cDNA showed significant NO syn- 
thase activity. The activity using the pcDNA I vector 
was higher than that using pcDL-SRa vector (Fig. 2A). 
The expressed activity was dependent on Ca’+, CaM, 
and NADPH, partially dependent on BH,, and mark- 
edly inhibited by NMA and NNA (Fig. 2B). FAD and 
FMN did not significantly stimulate the activity. All the 
expressed NO synthase activity was in the 100 000 x g 
supernatant fraction, and the specific activity using 
pcDNA I vector was about 7-times higher than that 
from human cerebellum supernatant fraction (data not 
shown). Western blot analysis of the supernatant frac- 
tion of the transfected cells using an antibody prepared 
to purified rat brain enzyme [ 161 showed a single protein 
band of 160 kDa (data not shown). 
Northern blot analysis of poly(A)’ RNA from differ- 
ent human tissues of a 32-year-old male probed with 
32P-labeled cDNA revealed a single lo-kb mRNA for 
the NO synthase (Fig. 3). Levels of mRNA were more 
abundant in skeletal muscle than brain, lower in pan- 
creas, and not detected in heart, placenta, lung, liver, 
and kidney. For skeletal muscle and brain, we repeated 
the experiment using a poly(A)’ RNA preparation from 
a 15year-old female and obtained the same results. 
Hybridization of a j?-actin probe to the same filters 
showed comparable levels of B-actin mRNA in all sam- 
ples, and two forms of fi-actin mRNA, 2.0-kb and 1.8- 
kb forms, were detected in heart and skeletal muscle, 
which are typical characteristics of muscle tissue j?-actin 
(data not shown). 
Homogenates of human skeletal muscle tissue 
showed significant NO synthase activity that was higher 
than in human brain, whereas rat skeletal muscle failed 
to show the activity (Fig. 4A). Most of the NO synthase 
activity of human skeletal muscle was found in the su- 
pernatant of the KC1 wash, indicating that it is soluble 
and/or loosely bound to membranes. The NO synthase 
activity in skeletal muscle was dependent on Ca”, CaM, 
NADPH, and BH,, partially dependent on FAD and 
FMN, and markedly inhibited by NMA and NNA (Fig. 
4B). 
High levels of expression of NO synthase in human 
skeletal muscle was also confirmed by Western blot 
analysis. The antibody against rat brain NO synthase 
2500 
2000 
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500 
0 
A 
0 Supetnatant 
KCI wash 
n Pellet 
Fig. 4. NO synthase activity in skeletal muscle and brain from human and rat. (A) NO synthase activity in the supernatant, KCI wash and pellet 
was assayed as described in Materials and Methods. (B) NO synthase activity was measured in a homogenate of human skeletal muscle under the 
various conditions indicated. Results are the means of duplicate determinations. 
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anti-type I anti-type I I I 
Fig. 5. Western blot analysis of NO synthase in human skeletal muscle. 50 pg of homogenate protein from human brain and skeletal muscle were 
separated by SDS-PAGE, transferred to nitrocellulose membrane and probed with the antibody against rat brain NO synthase (anti-type I) or with 
the antibody against bovine aortic endothelial NO synthase (anti-type III). Rat brain supernatant (anti-type I) or bovine aortic endothelial cells 
homogenate (anti-type III) were used as positive controls. 
recognized a single 160 kDa protein band in human 
skeletal muscle (as well as human and rat brain). No 
protein band was detected by the antibody against en- 
dothelial NO synthase (Fig. 5). 
4. DISCUSSION 
NO synthase exists in multiple isoforms, some of 
which have been purified and characterized (type I from 
brain type, type II from induced macrophages, type III 
from endothelial cells [20]). Recently, cDNAs for three 
of these isoenzymes have been cloned and the structural 
differences between these three isoforms became appar- 
ent [12,21-251. In the present study, we identified the 
cDNA clones that encode the entire sequence of human 
NO synthase type I from cerebellum. We found an over- 
all identity between the human and rat brain type I 
enzyme of 93%. All the suggested binding sites for var- 
ious co-factors were identical, and the possible phos- 
phorylation sites by protein kinases were also highly 
conserved, suggesting that the two enzymes share the 
same mechanisms of regulation. Regulation of NO syn- 
thase type I by phosphorylation has been suggested 
[14,26,27]. In addition, we compared the amino acid 
sequence of human NO synthase type I with the amino 
acid sequences of the recently cloned mouse macro- 
phage type II [2 1,221 and bovine and human endothelial 
cell type III [23-251 enzymes. The human type I enzyme 
showed 53% and 57% identity to type II and type III 
enzymes, respectively (data not shown). There is a 
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Volume 316, number 2 FEBSLETTERS January 1993 
highly conserved region near the center (residues 384 
703 in human NO synthase type I) in all the types of NO 
synthase, suggesting that this region could be the poten- 
tial arginine recognition domain and/or the BH, bind- 
ing domain. 
As expected from the high homology with the rat 
brain enzyme, expressed human NO synthase type I 
showed properties similar to that of rat NO synthase 
type I. It was completely dependent on Ca2’, CaM and 
NADPH, inhibited by NMA and NNA, and all the 
activity was localized in the cytosolic fraction of the 
COS-1 cells. It was only partially dependent on BH,, 
and FAD and FMN did not stimulate the activity, 
probably because the expressed enzyme already con- 
tains tightly bound BH,, FAD and FMN. Purified rat 
NO synthase type I contains BH,, FAD and FMN [28]. 
Analysis by Northern blot showed hybridization of 
NO synthase cDNA to a lo-kb mRNA that is similar 
in size to the rat brain NO synthase type I [12] but much 
larger than that of NO synthases type II and type III 
(4.4 kb or 5-6 kb for type II [21,22] and 4.4 kb or 4.8 
kb for type III [23-251). When the filter from the North- 
ern blot was washed in less stringent conditions, we 
detected faint 4.4-kb bands in all the human tissues 
tested, including skeletal muscle, which probably repre- 
sent mRNA of endothelial type III enzyme (data not 
shown). We detected some mRNA for NO synthase 
type I in pancreas. It has been suggested that NO syn- 
thase type I is present in rat pancreatic B cells [29]. 
Surprisingly, more mRNA for NO synthase type I is 
transcribed in skeletal muscle than in brain. It is un- 
likely that this derives from contaminating tissue or cells 
(for example, neuronal or para-neuronal cells), because 
the poly(A)’ RNA preparations from two different 
human sources showed the same result. In contrast, 
mRNA of NO synthase type I was not detected in rat 
skeletal muscle [12]. In addition to the mRNA, we de- 
tected high enzyme activity (Fig. 4) and the specific type 
I immuno-reactive protein of NO synthase in human, 
but not rat, skeletal muscle (Fig. 5). Most of the ex- 
pressed NO synthase in human skeletal muscle seems to 
be type I (brain type); the mRNA is about 10 kb (Fig. 
3), the expressed protein cross-reacted only with type I 
specific antibody, and the specific band of NO synthase 
in skeletal muscle migrated at a 160 kDa region similar 
to the rat brain NO synthase protein (Fig. 5). 
Whether the human is the only species expressing 
high levels of type I NO synthase in skeletal muscle, and 
the potential function of this NO synthase, is presently 
being explored. 
Acknowledgements: We thank Y. Takebe (National Institute of 
Health, Tokyo, Japan) for providing the pcDL-SRa expression vector, 
and Laura Gehrke and Zei-Jing Huang (Abbott Laboratories) for 
their skillful technical assistance. This work was supported in part by 
Grants DK 30787 and HL 28474 from the National Institutes of 
Health, USA. 
180 
REFERENCES 
PI 
121 
[31 
[41 
151 
161 
171 
PI 
[91 
PO1 
1111 
1121 
P31 
[I41 
[I51 
[I61 
[I71 
V81 
1191 
PO1 
Pll 
LQI 
[231 
(241 
1251 
WI 
~271 
PI 
[291 
1301 
Ishii, K., Gorsky, L.D., Forstermann, U. and Murad, F. (1989) 
J. Appl. Cardiol. 4, 505-512. 
Murad, F., Ishii, K., Gorsky, L., Fiistennann, U., Kerwin, J.F. 
and Heller, M. (1990) Nitric Oxide from L-Arginine: A Bioregula- 
tory System (S. Moncada and E.A. Higgs, eds.) pp. 301-315, 
Elsevier, Amsterdam. 
Garthwaite, J. (1991) Trends Neurosci. 14. 60-67. 
Knowles, R.G., Palacios, M., Palmer, R.M.J. and Moncada, S. 
(1989) Proc. Nat]. Acad. Sci. USA 86, 5159-5162. 
Fiirstermann, U., Gorsky, L.D., Pollock, J.S., Ishii, K., Schmidt, 
H.H.H.W., Heller, M. and Murad, F. (1990) Mol. Pharmacol. 38, 
7-13. 
Bredt, D.S. and Snyder, S.H. (1990) Proc. Nat]. Acad. Sci. USA 
87, 682685. 
Shibuki, K. and Okada, D. (1991) Nature 349, 326328. 
Biihme, G.A., Bon, C., Stutzman, J.-M., Doble, A. and Blan- 
chard, J.-C. (1991) Eur. J. Pharmacol. 199, 379-381. 
O’Dell, T.J., Hawkins, R.D., Kandel, E.R. and Arancio, 0. 
(1991) Proc. Nat]. Acad. Sci. USA 88, 11285-l 1289. 
Schuman, E.M. and Madison, D.V. (1991) Science 254. 15033 
1506. 
Haley, J.E., Wilcox, G.L. and Chapman, P.F. (1992) Neuron 8. 
21 l-216. 
Bredt, D.S., Hwang, P.M., Glatt, C.E., Lowenstein, C.. Reed, 
R.R. and Snyder, S.H. (1991) Nature 351. 714-718. 
Takebe, Y., Seiki, M., Fujisawa, J., Hoy, P., Yokota, K., Arai, 
K., Yoshida, M. and Arai, N. (1988) Mol. Cell. Biol. 8.466472. 
Nakane, M., Mitchell, J., Forstermann, U. and Murad. F. (1991) 
Biochem. Biophys. Res. Commun. 180, 13961402. 
Bradford, M.M. (1976) Anal. Biochem. 72. 248-254. 
Schmidt, H.H.H.W., Gagne, G.D., Nakane, M., Pollock, J.S.. 
Miller, M.F. and Murad, F. (1992) J. Histochem. Cytochem. 40, 
1439-1456. 
Pollock, J.S., Nakane, M.. Buttery, L.D.K., Martinez, A., Sprm- 
gall, D., Polak, J.M., Fiirstermann, U. and Murad, F.J. Clin. 
Invest. (submitted). 
Kozak, M. (1984) Nucleic Acid Res. 12, 857-872. 
Schmidt, H.H.H.W. and Murad, F. (1991) Biochem. Biophys. 
Res. Commun. 181, 1372-1377. 
Forstermann, U., Schmidt, H.H.H.W., Pollock, J.S., Sheng, H., 
Mitchell, J.A., Warner, T.D., Nakane, M. and Murad, F. (1991) 
Biochem. Pharmacol. 42, 1849-1857. 
Lyons, C.R., Orloff. G.J. and Cunningham, J.M. (1992) J. Biol. 
Chem. 267, 637&6374. 
Xie, Q., Cho, H.J.. Calaycay, J., Mumford, R.A., Swiderek, 
K.M., Lee, T.D.. Ding, A., Troso, T. and Nathan, C. (1992) 
Science 256, 2255228. 
Sessa, W.C., Harrison, J.K., Barber, C.M., Zeng, D.. Durieux. 
M.E., D’Angelo, D.D.. Lynch, K.R. and Peach, M.J. (1992) J. 
Biol. Chem. 267, 1527415276. 
Lamas, S., Marsden, P.A.. Li. G.K., Tempst, P. and Michel, T. 
(1992) Proc. Nat]. Acad. Sci. USA 89, 6348-6352. 
Marsden. P.A.. Schappert, K.T.. Chen, H.S., Flowers, M., Sun- 
dell, C.L., Wilcox, J.N., Lamas, S. and Michel, T. (1992) FEBS 
Lett. 307, 2877293. 
Briine, B. and Lapetina. E.G. (1991) Biochem. Biophys. Res. 
Commun. 181, 921-926. 
Bredt, D.S., Ferris, C.D. and Snyder, H. (1992) J. Biol. Chem. 
267, 1097610981. 
Schmidt, H.H.H.W., Smith, R.M., Nakane, M. and Murad, F. 
(1992) Biochemistry 3 1. 324333249. 
Schmidt, H.H.H.W., Warner, T.D., Ishii, K., Sheng, H. and 
Murad. F. (1992) Science 255, 721-723. 
Gribskov. M. and Burgess, R.R. (1986) Nucleic Acids Res. 14, 
674556763. 
